| Top 3 Health Care Stocks That Are Preparing To Pump This Quarter |
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. |
benzinga.com |
2025-05-09 11:16:56 |
Czytaj oryginał (ang.) |
| RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript |
RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President & Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Steve Lichtman - Oppenheimer David Saxon - Needham & Company Adam Maeder - Piper Sandler Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Craig Bijou - Bank of America Tom Stephan - Stifel Operator Thank you for standing by. At this time, I would like to welcome everyone to the RxSight First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-08 03:04:59 |
Czytaj oryginał (ang.) |
| RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates |
RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.12 per share a year ago. |
zacks.com |
2025-05-08 01:00:40 |
Czytaj oryginał (ang.) |
| RxSight, Inc. to Present at the Bank of America Healthcare Conference |
ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas. |
globenewswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:05:56 |
Czytaj oryginał (ang.) |
| RxSight price target lowered to $17 from $22 at Wells Fargo |
Wells Fargo lowered the firm's price target on RxSight to $17 from $22 and keeps an Equal Weight rating on the shares following the conference call to discuss the preliminary Q1 2025 sales results and lowered FY25 guidance. The company called out weak LAL volume trends through Q1, especially March, competitive product launches, and recessionary concerns, Wells notes. 09 May |
https://thefly.com |
2025-04-07 10:27:23 |
Czytaj oryginał (ang.) |
| RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) |
RxSight posted a sequential revenue decline, revealing cracks in momentum despite earlier signs of profitability. Revised 2025 outlook and lack of expected profitability suggest earlier optimism was premature. The competitive landscape has intensified with new IOL products from Johnson & Johnson and Rayner, challenging RxSight's unique LAL technology. |
seekingalpha.com |
2025-04-03 21:57:31 |
Czytaj oryginał (ang.) |
| RxSight, Inc. (RXST) Q1 2025 Preliminary Results Conference Call (Transcript) |
RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Preliminary Results Conference Call April 3, 2025 8:00 AM ET Company Participants Oliver Moravcevic - VP, IR Dr. Ron Kurtz - Director, Co-President and CEO Shelley Thunen - Assistant Secretary, Co-President and CFO Conference Call Participants Ryan Zimmerman - BTIG Xuyang Li - Jefferies Robert Marcus - JPMorgan Steve Lichtman - Oppenheimer David Saxon - Needham Danielle Antalffy - UBS Operator Thank you for standing by, and welcome to the RxSight conference call. All lines have been placed on mute to prevent any background noise. |
seekingalpha.com |
2025-04-03 19:54:04 |
Czytaj oryginał (ang.) |
| RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance |
ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. |
globenewswire.com |
2025-04-03 00:00:00 |
Czytaj oryginał (ang.) |
| RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference |
ALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 24th Annual Needham Virtual Healthcare Conference. |
globenewswire.com |
2025-03-25 18:05:00 |
Czytaj oryginał (ang.) |
| RxSight, Inc. (RXST) Q4 2024 Earnings Call Transcript |
RxSight, Inc. (NASDAQ:RXST ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Oliver Moravcevic - VP, IR Ron Kurtz - President and CEO Shelley Thunen - CFO Conference Call Participants Lily Lozada - JPMorgan Ryan Zimmerman - BTIG Steve Lichtman - Oppenheimer David Saxon - Needham Lei Huang - Wells Fargo Danielle Antalffy - UBS Thomas Stephan - Stifel Operator Ladies and gentlemen, thank you for standing by. My name is Nasrin and I will be your conference operator today. |
seekingalpha.com |
2025-02-26 08:35:46 |
Czytaj oryginał (ang.) |
| RxSight, Inc. (RXST) Misses Q4 Earnings Estimates |
RxSight, Inc. (RXST) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.26 per share a year ago. |
zacks.com |
2025-02-25 20:56:10 |
Czytaj oryginał (ang.) |
| RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance |
ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December 31, 2024. |
globenewswire.com |
2025-02-25 18:05:00 |
Czytaj oryginał (ang.) |
| RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance |
ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance. |
globenewswire.com |
2025-01-12 11:30:00 |
Czytaj oryginał (ang.) |
| RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference |
ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference. |
globenewswire.com |
2025-01-02 18:05:00 |
Czytaj oryginał (ang.) |
| RxSight downgraded to Hold from Buy at Stifel |
Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm's latest deep-dive survey of surgeons leads to believe that the risk from U.S. premium IOL - intraocular lens - competition may be more material than investors appreciate, with JNJ's (JNJ) new Tecnis Odyssey lens "jumping off the page" in its findings and with Alcon's (ALC) PanOptix Pro around the corner, the analyst tells investors in a research note. Stifel adds that its longitudinal analysis shows the respondents' 2025 LAL - light adjustable lenses - volume expectations are moderately weakening, giving the firm pause around the intermediate-term LAL path ahead. RxSight +1.02 (+2.74%) Johnson & Johnson -1.16 (-0.80%) Alcon -0.56 (-0.66%) |
https://thefly.com |
2024-12-19 21:55:01 |
Czytaj oryginał (ang.) |
| Needham ups Alcon target, adds to Conviction List |
Needham earlier today raised the firm's price target on Alcon (ALC) to $108 from $103 and kept a Buy rating on the shares. The firm also added the stock to its Conviction List, replacing RxSight (RXST). Alcon's product launch lineup is one of the best it's been since its spin from Novartis, the analyst told investors in a research note. Needham expects the product launches to result in Alcon's revenue growth accelerating throughout 2025, which should drive multiple expansion. The firm made the stock a top pick for 2025. With the stock's valuation meaningfully below Alcon's historical range, risks around currency and commercial investments are baked in, making the risk/reward attractive, contended Needham. Alcon +1.88 (+2.24%) RxSight -0.1 (-0.26%) |
https://thefly.com |
2024-12-17 16:12:10 |
Czytaj oryginał (ang.) |
| RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye |
RxSight's light adjustable lenses [LAL] continue to gain traction in the $6 billion-plus cataract surgical market. In their Q3 earnings report, RxSight announced that 24,554 LALs were sold in Q3, representing an 80% YoY increase in volume compared to the same period last year. The company's healthy balance sheet supports continued efforts in driving adoption within the U.S. market, while also maintaining the necessary R&D investments to remain innovative in the long run. |
seekingalpha.com |
2024-11-29 14:04:22 |
Czytaj oryginał (ang.) |
| RxSight (RXST) Upgraded to Buy: Here's What You Should Know |
RxSight (RXST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-20 15:00:37 |
Czytaj oryginał (ang.) |
| RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript |
RxSight, Inc. (NASDAQ:RXST ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Conference Call Participants Lilia Lozada - J.P. Morgan Iseult McMahon - BTIG Lei Huang - Wells Fargo Craig Bijou - Bank of America Young Li - Jefferies Tom Stephan - Stifel Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & Company Operator Thank you for standing by. |
seekingalpha.com |
2024-11-09 15:32:04 |
Czytaj oryginał (ang.) |
| RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3 |
RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.35 per share a year ago. |
zacks.com |
2024-11-07 22:01:11 |
Czytaj oryginał (ang.) |
| RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024 |
ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-10-24 20:05:00 |
Czytaj oryginał (ang.) |
| RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences |
ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September. |
globenewswire.com |
2024-08-22 20:05:00 |
Czytaj oryginał (ang.) |
| Investing In The Future Of Cataract Surgery: The RxSight Advantage |
RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly expanding, with RxSight well-positioned to capitalize on the growing demand for premium IOLs. Impressive financial performance in Q2 2024, with significant revenue growth, gross profit margin improvement, and raised full-year revenue guidance. |
seekingalpha.com |
2024-08-13 20:50:30 |
Czytaj oryginał (ang.) |
| Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect? |
The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-08-12 14:55:37 |
Czytaj oryginał (ang.) |
| RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript |
RxSight, Inc. (NASDAQ:RXST ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Oliver Moravcevic - Vice President, Investor Relations Conference Call Participants Ryan Zimmerman - BTIG Robbie Marcus - J.P. Morgan Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & Company Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Tom Stephan - Stifel Operator Good day and thank you for standing by. |
seekingalpha.com |
2024-08-06 01:45:06 |
Czytaj oryginał (ang.) |
| RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2 |
RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.40 per share a year ago. |
zacks.com |
2024-08-05 23:10:35 |
Czytaj oryginał (ang.) |
| RxSight, Inc. Reports Second Quarter 2024 Financial Results |
ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024. |
globenewswire.com |
2024-08-05 20:05:00 |
Czytaj oryginał (ang.) |
| The 3 Best Med Tech Stocks to Buy Now |
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments. |
investorplace.com |
2024-08-05 15:20:44 |
Czytaj oryginał (ang.) |
| Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround |
RxSight (RXST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2024-07-29 14:35:19 |
Czytaj oryginał (ang.) |
| RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024 |
ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-07-22 20:05:00 |
Czytaj oryginał (ang.) |
| RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for RxSight (RXST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-07-12 14:36:10 |
Czytaj oryginał (ang.) |
| RxSight, Inc. To Participate in the Truist Securities Medtech Conference |
ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Truist Securities MedTech Conference. |
globenewswire.com |
2024-06-05 20:05:00 |
Czytaj oryginał (ang.) |
| What Makes RxSight, Inc. (RXST) a Strong Momentum Stock: Buy Now? |
Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-05-28 17:01:36 |
Czytaj oryginał (ang.) |